Business
DRI Healthcare Trust Announces Acquisition of a Royalty Interest in the Worldwide Sales of pegcetacoplan Including Empaveli® /Aspaveli® for the Treatment of Paroxysmal Nocturnal Hemoglobinuria
DRI Healthcare Trust Announces Acquisition of a Royalty Interest in the Worldwide Sales o...
About this update from Dri Healthcare Trust
[{"type":"text","content":"\n \n \n \n DRI Healthcare Trust Announces Acquisition of a Royalty Interest in the Worldwide Sales of pegcetacoplan Including Empaveli® /Aspaveli® for the Treatment of Paroxysmal Nocturnal Hemoglobinuria\n \n \n /* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n.prntac{\nTEXT-ALIGN: CENTER\n}\n \n \n \n \n \n \n Canada NewsWire\n \n \n \n \n \n – Transaction builds on DRI's history of investing in innovative therapies for the treatment of\n \n hematological conditions –\n \n \n \n \n – Creative deal structure provides DRI with option to increase interest in the future –\n \n \n \n \n – Fast-growing product with long-term horizon extends the duration of DRI's cash flows –\n \n \n \n \n \n TORONTO\n \n \n ,\n \n \n July 21, 2022\n \n \n /CNW/ - DRI Healthcare Trust (TSX: DHT.UN) (TSX: DHT.U) (\"DRI\" or \"the Trust\") today announced that a wholly-owned subsidiary of DRI has acquired a royalty interest in pegcetacoplan for an upfront purchase price of\n \n US$24.5 million\n \n , with an option to increase its interest in pegcetacoplan in the future.\n \n \n \n \n \n \n \n \n \n Pegcetacoplan is the active molecule in the first targeted C3 therapy for use in adults with Paroxysmal Nocturnal Hemoglobinuria (\"PNH\") and was approved by the US Food and Drug Administration (\"FDA\") and the European Medicines Agency in 2021. It is marketed in the US by biopharmaceutical company, Apellis Pharmaceuticals Inc. (\"Apellis\"), under the brand name Empaveli and outside the US by rare disease-focused biopharmaceutical company, Swedish Orphan Biovitrum AB, including in the EU under the brand name Aspaveli.\n \n \n \"We are very pleased to announce the addition of pegcetacoplan to our portfolio,\" said\n \n Behzad Khosrowshahi\n \n , Chief Executive Officer of DRI Healthcare Trust. \"Empaveli and Aspaveli provide a novel treatment option for a very serious disease and represent a significant advancement in the standard of care. The innovative option element of the deal structure gives us the ability to increase the Trust's exposure to pegcetacoplan s...